AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03204955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride (23.4%)
Description: Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy.
Study NCT03204955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PlasmaLyte
Description: PlasmaLyte is an isotonic IV solution that mimics human physiological plasma electrolyte concentrations, osmolality and pH.
Study NCT03204955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PlasmaLyte
Description: PlasmaLyte is an isotonic IV solution that mimics human physiological plasma electrolyte concentrations, osmolality and pH.
Study NCT04747730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation training
Description: The programme targets inmates in HMP Warren Hill who are eligible to learn the meditation technique, who are staying in prison for at least six months since the beginning of the programme and who provide the signed informed consent. The sample of eligible inmates is approximately 190 inmates out of 250 currently in the prison. Inmates will be contacted by the research team in prison during introductory sessions of the research intervention.
Study NCT01714804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accell Evo3 Prospective Use
Study NCT01210430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Subjects will receive placebo or losartan for 4 weeks. Days 1-7, subjects will receive 12.5mg of Losartan or placebo. Days 7-14, subjects will receive 25mg of Losartan or placebo. Days 14-28, subjects will receive 50mg of Losartan or placebo.
Study NCT01210430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid (Vitamin C)
Description: Subjects will receive 60mg/kg of Ascorbic Acid over 20 minutes followed by a maintenance infusion of 20mg/kg.
Study NCT01210430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Subjects will receive 60mg/kg of normal saline over 20 minutes followed by a maintenance infusion of 20mg/kg of normal saline.
Study NCT00490256 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Selective Cerebral Perfusion
Description: Modified Selective perfusion is a cardiopulmonary bypass circuit that has been modified to allow blood flow to the lower body as well as the upper body while the surgery is being performed.
Study NCT02168530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo administered daily orally
Study NCT02168530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: vismodegib 150 mg administered daily orally
Study NCT02592538 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: radiofrequency ablation
Description: All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture.
Study NCT02592538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture.
Study NCT02592538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: In the RFA plus S-1 group, treatment with S-1 began within 1 month after RFA. Based on the patient's body surface area, S-1 was administered as follows: when the level of total bilirubin was less than 2 mg/dl. Based on the body surface area, S-1 was administered if \<1.25 m2, 80 mg/day; if 1.25-1.5 m2, 100 mg/day; if≥1.5 m2, 120 mg/day. S-1 was administered orally twice daily for 14 days, followed by 7 days without treatment.
Study NCT02592538 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Stent
Description: Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction
Study NCT02592538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent
Description: Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction
Study NCT00929825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical stimulation (Elastomers)
Description: The instrument of mastication, sialogogue should be used 4 times a day for 10 minutes each time always after meals
Study NCT00929825 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TENS
Description: transcutaneous electrical stimulation
Study NCT02804347 — intervention group
Intervention type: OTHER
Intervention: Cognitive Batteries
Description: Participants will conduct the following cognitive batteries: DSST, TMT A \& B, RAVLT
Study NCT01177228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab for intravenous infusion
Study NCT01177228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion
Study NCT01083537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 1) Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.~1. Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn~2. Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour
Study NCT01083537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 2) Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.~1. Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo~2. Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn~3. Hydration: Infuse Paclitaxel in 250cc NS over 1 hour
Study NCT00472069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplantation of the squeletic muscular cells
Description: transplantation of the squeletic muscular cells
Study NCT01355601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Beverage
Description: Nutritional Beverage with varying types and levels of carbohydrates
Study NCT01355601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Beverage
Description: Nutritional beverage with varying types and levels of carbohydrates
Study NCT00779779 — intervention group
Intervention type: BIOLOGICAL
Intervention: Rotarix™
Description: Two oral doses, with at least 4 weeks interval in-between
Study NCT03953339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Release or no release of the suprascapular nerve
Study NCT04106336 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Repetitive transcranial magnetic stimulation (rTMS) will be done for cannabis addict
Study NCT02822040 — intervention group
Intervention type: OTHER
Intervention: Intraoral Scan
Description: All patients will have an intraoral scan performed for measurements to be taken on.
Study NCT03953339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Release or no release of the suprascapular nerve
Study NCT01146314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Focused Lifestyle Intervention
Description: The lifestyle intervention is a 6-month intervention study lasting 6 months. The intervention is 14 sessions and conducted by a dietician and psychologist in a group setting with each intervention session lasting 90 minutes. The sessions are conducted weekly, biweekly, and monthly over the course of 6 months.
Study NCT04392063 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Melatonin 3 mg
Description: The children received crushed Melatonin 3-mg tablets daily, 30-minutes before bedtime for 3-months.
Study NCT02817035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noninvasive mechanical ventilation
Description: To examined the physiological signals of patients and healthy subjects during spontaneous breathing and noninvasive mechanical ventilation.
Study NCT02013492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol hydrochloride
Description: Given PO
Study NCT02013492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative Studies
Description: Correlative studies will be conducted using the following materials:~* Plasma derived from peripheral blood.~* Peripheral blood mononuclear cells (PBMC) derived from patient blood~* Tumor tissue obtained at the time of core needle biopsy at the 2 month time point.~* Paraffin-embedded tumor tissue obtained pre-therapy to make the diagnosis of metastatic disease.
Study NCT04069130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg of BIA 5-1058
Description: 1 x 400 mg capsule Oral, Fasted
Study NCT04045444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking
Description: Every participants will performed a set of tasks of 2 min. Each task will be separated by a 2 min resting period. The tasks will be walking at 3 km/h, walking while doing the cognitive task, walking at the preferred speed, walking at the preferred speed while doing the cognitive task.
Study NCT04045444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive task
Description: Every participants will performed a set of tasks of 2 min. Each task will be separated by a 2 min resting period. The tasks will be a cognitive task, a control cognitive task.
Study NCT03278535 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CAREN-based gait analysis
Description: subjects only walk at CAREN at different speed
Study NCT03907163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Capsules containing 5 mg Dronabinol
Study NCT03907163 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules identical in appearance to dronabinol
Study NCT03547401 — intervention group
Intervention type: DEVICE
Intervention: Ankle Non-invasive Blood pressure measurement
Description: Non-invasive blood pressure measured simultaneously at the arm (model IntelliVue M8105a MP5 Phillips, calibrated).
Study NCT03547401 — intervention group
Intervention type: DEVICE
Intervention: Arm Non-invasive Blood pressure measurement
Description: Non-invasive blood pressure measured simultaneously at the ankle (model IntelliVue M8105a MP5 Phillips, calibrated).
Study NCT02565563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eye Movement Desensitisation Reprocessing
Description: The purpose of this study is not to assess the device itself. The new device will seek to measure heart rate variabilty during the administration of the treatment EMDR. It will measure the patients sympathetic nervous systems (anxiety arousal). Previous reseach studies have used Electrocardiography (ECG) and the purpose of this study is to determine whether or not this device will obtain similar findings as ECG has done.
Study NCT02565563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartMath measuring Heart Rate Variability (HRV)
Description: This small device will be attached to the patients finger to allow their heart rate variability to be measured.
Study NCT02393872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feel4Diabetes-intervention
Description: Community-based intervention.
Study NCT02623010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imbruvica
Description: Bruton's Tyrosine Kinase Inhibitor Ibrutinib as maintenance treatment in elderly patients with primary CNS lymphoma following first line chemotherapy treatment
Study NCT04107922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glicoset
Description: Patients will take a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate
Study NCT04107922 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take placebo
Study NCT01654601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWCZP
Description: Multiple dose
Study NCT01654601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozaril
Description: multiple-dose
Study NCT01119898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PENNSAID Gel
Description: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
Study NCT01119898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
Study NCT01834508 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
Study NCT01122381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethosuximide
Description: ethosuximide (ESX)
Study NCT01122381 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: placebo
Study NCT02513069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Description: Participants will be prescribed one form of nicotine replacement rescue treatment (i.e., gum, lozenge), and may choose nicotine gum as the preferred rescue treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings.
Study NCT02513069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine gum
Description: Participants will be prescribed one form of nicotine replacement rescue treatment (i.e., gum, lozenge), and may choose nicotine gum as the preferred rescue treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings.
Study NCT02513069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile contingency management
Description: Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided reinforcement for videos that suggest smoking abstinence.
Study NCT02513069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Description: Participants receive five sessions of cognitive-behavioral telephone counseling, and a participant manual. The telephone counseling protocol included in this application is based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation and is informed by behavioral treatment principles .
Study NCT02513069 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone counseling
Description: Participants receive five sessions of cognitive-behavioral telephone counseling, and a participant manual. The telephone counseling protocol included in this application is based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation and is informed by behavioral treatment principles .
Study NCT02513069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Participants will be prescribed nicotine patches to be used during the post-quit phase of the study.
Study NCT02513069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Participants will be prescribed nicotine patches to be used during the post-quit phase of the study.
Study NCT02513069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: Participants will be prescribed one form of nicotine replacement rescue treatment (i.e., gum, lozenge), and may choose nicotine lozenge as the preferred rescue treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings.
Study NCT02513069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine lozenge
Description: Participants will be prescribed one form of nicotine replacement rescue treatment (i.e., gum, lozenge), and may choose nicotine lozenge as the preferred rescue treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings.
Study NCT02513069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart phone
Description: Participants in the experimental condition will be loaned a smart phone to use during the mobile contingency management intervention period. The phone will be used to record videos of carbon monoxide readings to determine smoking abstinence.
Study NCT02513069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbon monoxide monitor
Description: Participants in the experimental condition will be loaned a CO monitor to use during the mobile contingency management intervention period. The monitor will be used to determine carbon monoxide content in the breath as a measurement of smoking.
Study NCT00116844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Description: Valtrex 1g once daily
Study NCT00116844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study NCT02640248 — intervention group
Intervention type: DEVICE
Intervention: Cuff ETT
Study NCT04418635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prosta-OK® Neo or Prosta-OK® Neo-matched placebo
Description: the patient planed to receive Tamsulosin 0.2mg once daily is randomized to the experiment group or placebo group. After randomization, the patient received Tamsulosin therapy with Prosta-OK® Neo or Prosta-OK® Neo-matched placebo 707mg 2 tablets twice daily for 85 days.
Study NCT04418635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Prosta-OK® Neo or Prosta-OK® Neo-matched placebo
Description: the patient planed to receive Tamsulosin 0.2mg once daily is randomized to the experiment group or placebo group. After randomization, the patient received Tamsulosin therapy with Prosta-OK® Neo or Prosta-OK® Neo-matched placebo 707mg 2 tablets twice daily for 85 days.
Study NCT02977559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube Suction Disposable
Description: Device for ventilation
Study NCT02977559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway AuraGain
Description: Ventilation device
Study NCT03907527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGN-3005 UltraCAR-T cells
Description: Given IP
Study NCT03907527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGN-3005 UltraCAR-T cells
Description: Given IV
Study NCT02294396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron tablet
Description: orally administered at a dose of 1 tablet once daily after breakfast
Study NCT01873430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Study NCT04472442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia
Description: Acute intermittent treatment (AIH) will be initiated using an oxygen generator (Model HYP-123, Hypoxico Inc, New York, NY, and participants will be seated comfortably and fitted with a non-rebreather mask. AIH (using 9% O2) will be provided in 60 s intervals and repeated 15 times with alternating 60 s intervals of normoxia (21% O2). Continuous pulse oximetry (Masimo 7, Irvine CA) will be monitored to ensure oxygen saturation of 82-85%. Signs and symptoms of distress with AIH exposure will be noted throughout, with HR and blood pressure taken every 3-5 minutes and documented.~High-intensity training will then be performed (40 min of walking training up to 70-80% maximum heart rate within 1 hr).
Study NCT04472442 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham hypoxia
Description: Sham acute intermittent treatment (sham AIH) will be initiated using an oxygen generator (Model HYP-123, Hypoxico Inc, New York, NY, and participants will be seated comfortably and fitted with a non-rebreather mask. Sham AIH (using 20% O2) will be provided in 60 s intervals and repeated 15 times with alternating 60 s intervals of normoxia (21% O2). Continuous pulse oximetry (Masimo 7, Irvine CA) will be monitored to ensure oxygen saturation of 82-85%. Signs and symptoms of distress with AIH exposure will be noted throughout, with HR and blood pressure taken every 3-5 minutes and documented.~High-intensity training will then be performed (40 min of walking training up to 70-80% maximum heart rate within 1 hr).
Study NCT01963858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional relaxation
Description: Functional relaxation during colonoscopy
Study NCT01963858 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No relaxation
Description: No relaxation during colonoscopy
Study NCT00660764 — intervention group
Intervention type: DRUG
Intervention: Rosuvastatin
Description: Oral